Skip to main content

George K. Lewis, PhD

Robert C. Gallo, MD Endowed Professor in Translational Medicine

Academic Title:

Professor

Primary Appointment:

Microbiology and Immunology

Additional Title:

The Robert C. Gallo, M.D., Professor in Translational Medicine; Director, Division of Vaccine Research, Institute of Human Virology

Location:

Institute of Human Virology N660

Phone (Primary):

(410) 706-4668

Education and Training

B.S., 1970 University of Mississippi, Biology (major) Chemistry (minor)
Ph.D., 1974 University of Mississippi, Immunology (in Dept. of Biology), Julius M. Cruse, M.D., Ph.D., (Mentor)
Postdoctoral Fellow, 1974–1978 UCSF. Department of Microbiology and Immunology,  Immunology/Immunochemistry,  Joel W. Goodman, Ph.D. (Mentor)

Research/Clinical Keywords

HIV Vaccine Development, Immunology, Structural Biology, Non-human Primates

Highlighted Publications

1.         W. D. Tolbert et al., Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the                  C11 Region. Structure,  (2017).

2.         M. Mengistu et al., Patterns of conserved gp120 epitope presentation on attached HIV-1 virions. Proc Natl Acad Sci U S A,  (2017).

3.         G. K. Lewis et al., Beyond Viral Neutralization. AIDS Res Hum Retroviruses 33, 760-764 (2017).

4.         G. K. Lewis, M. Pazgier, A. L. DeVico, Survivors Remorse: antibody-mediated protection against HIV-1. Immunological reviews 275, 271-284 (2017).

5.         A. Schmaljohn, G. K. Lewis, Cell-targeting antibodies in immunity to Ebola. Pathogens and disease 74, ftw021 (2016).

Additional Publication Citations

 

 

1.         W. D. Tolbert et al., Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region. Structure,  (2017).

2.         M. Mengistu et al., Patterns of conserved gp120 epitope presentation on attached HIV-1 virions. Proc Natl Acad Sci U S A,  (2017).

3.         G. K. Lewis et al., Beyond Viral Neutralization. AIDS Res Hum Retroviruses 33, 760-764 (2017).

4.         G. K. Lewis, M. Pazgier, A. L. DeVico, Survivors Remorse: antibody-mediated protection against HIV-1. Immunological reviews 275, 271-284 (2017).

5.         W. D. Tolbert et al., Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region. Structure 24, 697-709 (2016).

6.         J. A. Schwartz et al., An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques. Clinical and vaccine immunology : CVI 23, 618-627 (2016).

7.         A. Schmaljohn, G. K. Lewis, Cell-targeting antibodies in immunity to Ebola. Pathogens and disease 74, ftw021 (2016).

8.         M. M. Sajadi et al., lambda Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies. The Journal of infectious diseases 213, 156-164 (2016).

9.         C. Orlandi, R. Flinko, G. K. Lewis, A new cell line for high throughput HIV-specific antibody-dependent cellular cytotoxicity (ADCC) and cell-to-cell virus transmission studies. Journal of immunological methods 433, 51-58 (2016).

10.       G. K. Lewis, The first 24 h: targeting the window of opportunity for antibody-mediated protection against HIV-1 transmission. Current opinion in HIV and AIDS 11, 561-568 (2016).

11.       G. Kaplan, A. Roitburd-Berman, G. K. Lewis, J. M. Gershoni, Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies. Journal of virology 90, 4481-4493 (2016).

12.       Y. Huang et al., Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. J Immunol 197, 4603-4612 (2016).

13.       N. Gohain et al., Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240. Scientific reports 6, 36685 (2016).

14.       M. Mengistu, K. Ray, G. K. Lewis, A. L. DeVico, Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells. PLoS pathogens 11, e1004772 (2015).

15.       G. K. Lewis, Honing a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potency. The Journal of clinical investigation, 1-4 (2015).

16.       M. W. Gonzalez, A. L. DeVico, G. K. Lewis, J. L. Spouge, Conserved molecular signatures in gp120 are associated with the genetic bottleneck during simian immunodeficiency virus (SIV), SIV-human immunodeficiency virus (SHIV), and HIV type 1 (HIV-1) transmission. Journal of virology 89, 3619-3629 (2015).

17.       M. W. Gonzalez, A. L. DeVico, G. K. Lewis, J. L. Spouge, Conserved molecular signatures in gp120 are associated with the genetic bottleneck during SIV, SHIV, and HIV-1 transmission. Journal of virology,  (2015).

18.       N. Gohain et al., Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. Journal of virology 89, 8840-8854 (2015).

19.       N. Gohain et al., Co-crystal structures of antibody N60-i3 and antibody JR4 in complex with gp120 define more Cluster A epitopes involved in effective antibody-dependent effector function against HIV-1. Journal of virology,  (2015).

20.       T. R. Fouts et al., Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A,  (2015).

21.       S. Ding et al., A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies. Journal of virology 90, 2127-2134 (2015).

22.       S. Ding et al., A Highly-Conserved Residue of the HIV-1-gp120 Inner Domain is Important for ADCC Responses Mediated by Anti-Cluster A Antibodies. Journal of virology,  (2015).

23.       A. L. DeVico, G. K. Lewis, R. C. Gallo, Modulating the durability of anti-HIV gp120 antibody responses after vaccination: a comment on Wilson & Karp (2015). Philosophical transactions of the Royal Society of London. Series B, Biological sciences 370,  (2015).

24.       N. Alsahafi et al., Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity. Journal of virology 90, 2993-3002 (2015).

25.       N. Alsahafi et al., Nef proteins from HIV-1 elite controllers are inefficient at preventing ADCC. Journal of virology,  (2015).

26.       M. Veillette et al., Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity. Journal of virology 88, 2633-2644 (2014).

27.       M. A. Thomas et al., HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. Virology 471-473C, 81-92 (2014).

28.       K. Ray et al., Antigenic properties of the HIV envelope on virions in solution. Journal of virology 88, 1795-1808 (2014).

29.       G. K. Lewis et al., Epitope target structures of Fc-mediated effector function during HIV-1 acquisition. Current opinion in HIV and AIDS 9, 263-270 (2014).

30.       G. K. Lewis, A. L. DeVico, R. C. Gallo, Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development. Proc Natl Acad Sci U S A 111, 15614-15621 (2014).

31.       G. K. Lewis, Role of Fc-mediated antibody function in protective immunity against HIV-1. Immunology 142, 46-57 (2014).

32.       M. K. Lafferty et al., Elevated suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated osteoclastogenesis in HIV transgenic rats. Pathogens and disease 71, 81-89 (2014).

33.       P. Acharya et al., Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. Journal of virology 88, 12895-12906 (2014).

34.       A. Roitburd-Berman, G. Dela, G. Kaplan, G. K. Lewis, J. M. Gershoni, Allosteric induction of the CD4-bound conformation of HIV-1 Gp120. Retrovirology 10, 147 (2013).

35.       G. K. Lewis, Jr., M. D. Langer, C. R. Henderson, Jr., R. Ortiz, Design and evaluation of a wearable self-applied therapeutic ultrasound device for chronic myofascial pain. Ultrasound in medicine & biology 39, 1429-1439 (2013).

36.       G. K. Lewis, Qualitative and Quantitative Variables that Affect the Potency of Fc- Mediated Effector Function In Vitro and In Vivo: Considerations for Passive Immunization Using Non-Neutralizing Antibodies. Current HIV research 11, 354-364 (2013).

37.       M. K. Lafferty et al., Elevated suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated osteoclastogenesis in HIV transgenic rats. Pathogens and disease,  (2013).

38.       Y. Guan et al., Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A 110, E69-78 (2013).

39.       H. M. Wang et al., [Identification of Env-specific monoclonal antibodies from Chinese HIV-1 infected person by B cell activation and RT-PCR cloning]. Bing du xue bao = Chinese journal of virology / [bian ji, Bing du xue bao bian ji wei yuan hui] 28, 358-365 (2012).

40.       M. M. Sajadi et al., Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma. Journal of virology 86, 5014-5025 (2012).

41.       R. Kong et al., Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. Journal of virology 86, 12115-12128 (2012).

42.       B. F. Haynes et al., Immune-correlates analysis of an HIV-1 vaccine efficacy trial. The New England journal of medicine 366, 1275-1286 (2012).

43.       M. Bonsignori et al., Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. Journal of virology 86, 11521-11532 (2012).

44.       M. M. Sajadi et al., Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr 57, 9-15 (2011).

45.       G. K. Lewis et al., Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins. Journal of virology 85, 13097-13104 (2011).

46.       K. C. Bagley, G. K. Lewis, T. R. Fouts, Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun. Clinical and vaccine immunology : CVI 18, 922-930 (2011).

47.       G. K. Lewis, Challenges of antibody-mediated protection against HIV-1. Expert review of vaccines 9, 683-687 (2010).

48.       A. Monaco et al., Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS letters 583, 3004-3008 (2009).

49.       Y. Guan et al., Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A 106, 3952-3957 (2009).

50.       L. Buonaguro et al., Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles. Journal of virology 83, 304-313 (2009).

51.       Y. Guan, S. Abdelwahab, R. Kamin-Lewis, A. L. DeVico, G. K. Lewis, Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands. PloS one 3, e3481 (2008).

52.       L. Buonaguro et al., Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC bioinformatics 9 Suppl 2, S5 (2008).

53.       H. Li et al., Synthesis and anti-HIV activity of trivalent CD4-mimetic miniproteins. Bioorganic & medicinal chemistry 15, 4220-4228 (2007).

54.       G. K. Lewis, Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet? Expert review of vaccines 6, 431-440 (2007).

55.       A. Heredia et al., CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1. Aids 21, 1317-1322 (2007).

56.       A. DeVico et al., Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A 104, 17477-17482 (2007).

57.       L. Buonaguro et al., Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. Journal of virology 80, 9134-9143 (2006).

58.       K. C. Bagley, S. F. Abdelwahab, R. G. Tuskan, G. K. Lewis, Cholera toxin indirectly activates human monocyte-derived dendritic cells in vitro through the production of soluble factors, including prostaglandin E(2) and nitric oxide. Clinical and vaccine immunology : CVI 13, 106-115 (2006).

59.       M. Popovic et al., Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci U S A 102, 14807-14812 (2005).

60.       G. K. Lewis, V. Load, Ed. (2005).

61.       K. C. Bagley, S. F. Abdelwahab, R. G. Tuskan, G. K. Lewis, Pasteurella multocida toxin activates human monocyte-derived and murine bone marrow-derived dendritic cells in vitro but suppresses antibody production in vivo. Infection and immunity 73, 413-421 (2005).

62.       E. Arico et al., Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. Journal of translational medicine 3, 45 (2005).

63.       E. Arico et al., Immature Monocyte Derived Dendritic Cells gene expression profile in response to Virus-Like Particles stimulation. Journal of translational medicine 3, 45 (2005).

64.       L. Sun, S. F. Abdelwahab, G. K. Lewis, A. Garzino-Demo, Recall antigen activation induces prompt release of CCR5 ligands from PBMC: implication in memory responses and immunization. International immunology,  (2004).

65.       W. Reid et al., HIV-1 transgenic rats develop T cell abnormalities. Virology 321, 111-119 (2004).

66.       J. Ni et al., Synthesis, conformation, and immunogenicity of monosaccharide-centered multivalent HIV-1 gp41 peptides containing the sequence of DP178. Bioorganic & medicinal chemistry 12, 3141-3148 (2004).

67.       H. Li et al., Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein. Bioconjug Chem 15, 783-789 (2004).

68.       K. C. Bagley, S. F. Abdelwahab, R. G. Tuskan, G. K. Lewis, Calcium signaling through phospholipase C activates dendritic cells to mature and is necessary for the activation and maturation of dendritic cells induced by diverse agonists. Clinical and diagnostic laboratory immunology 11, 77-82 (2004).

69.       D. Zagury et al., Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine & growth factor reviews 14, 123-137 (2003).

70.       T. R. Fouts et al., Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1. FEMS Immunol Med Microbiol 37, 129-134 (2003).

71.       K. C. Bagley et al., Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin. Vaccine 21, 3335-3341 (2003).

72.       K. C. Bagley, S. F. Abdelwahab, R. G. Tuskan, G. K. Lewis, An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants. Infection and immunity 71, 6850-6856 (2003).

73.       S. F. Abdelwahab et al., HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses. Proc Natl Acad Sci U S A 100, 15006-15010 (2003).

74.       J. H. Skurnick et al., Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. The Journal of infectious diseases 185, 428-438 (2002).

75.       D. M. Hone et al., Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments. J Hum Virol 5, 17-23 (2002).

76.       C. M. Finnegan, W. Berg, G. K. Lewis, A. L. DeVico, Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. Journal of virology 76, 12123-12134 (2002).

77.       A. L. Devico et al., Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine 20, 1968-1974 (2002).

78.       M. A. De Francesco et al., HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc Natl Acad Sci U S A 99, 9972-9977 (2002).

79.       K. C. Bagley, S. F. Abdelwahab, R. G. Tuskan, T. R. Fouts, G. K. Lewis, Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway. Infection and immunity 70, 5533-5539 (2002).

80.       K. C. Bagley, S. F. Abdelwahab, R. G. Tuskan, T. R. Fouts, G. K. Lewis, Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway. Journal of leukocyte biology 72, 962-969 (2002).

81.       M. T. Shata, M. S. Reitz, Jr., A. L. DeVico, G. K. Lewis, D. M. Hone, Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 20, 623-629 (2001).

82.       W. Reid et al., An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A 98, 9271-9276 (2001).

83.       R. Kamin-Lewis et al., Perforin-low memory CD8+ cells are the predominant T cells in normal humans that synthesize the beta -chemokine macrophage inflammatory protein-1beta. Proc Natl Acad Sci U S A 98, 9283-9288 (2001).

84.       C. M. Finnegan, W. Berg, G. K. Lewis, A. L. DeVico, Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. Journal of virology 75, 11096-11105 (2001).

85.       N. H. Carbonetti, R. G. Tuskan, G. K. Lewis, Stimulation of HIV gp120-specific cytolytic T lymphocyte responses in vitro and in vivo using a detoxified pertussis toxin vector. AIDS Res Hum Retroviruses 17, 819-827 (2001).

86.       M. T. Shata, L. Stevceva, S. Agwale, G. K. Lewis, D. M. Hone, Recent advances with recombinant bacterial vaccine vectors. Mol Med Today 6, 66-71 (2000).

87.       T. R. Fouts et al., Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex`. Journal of virology 74, 11427-11436 (2000).

88.       T. R. Fouts et al., Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. Journal of virology 74, 11427-11436 (2000).

89.       N. H. Carbonetti et al., Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway. Infection and immunity 67, 602-607 (1999).

90.       J. M. Burns, G. K. Lewis, A. L. DeVico, Soluble complexes of regulated upon activation, normal T cells expressed and secreted (RANTES) and glycosaminoglycans suppress HIV-1 infection but do not induce Ca(2+) signaling. Proc Natl Acad Sci U S A 96, 14499-14504 (1999).

91.       D. M. Hone, J. Powell, R. W. Crowley, D. Maneval, G. K. Lewis, Lipopolysaccharide from an Escherichia coli htrB msbB mutant induces high levels of MIP-1 alpha and MIP-1 beta secretion without inducing TNF-alpha and IL-1 beta. J Hum Virol 1, 251-256 (1998).

92.       L. A. Cavacini et al., Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses 14, 1271-1280 (1998).

93.       J. M. Burns, R. C. Gallo, A. L. DeVico, G. K. Lewis, A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling. The Journal of experimental medicine 188, 1917-1927 (1998).

94.       S. Wu, D. W. Pascual, G. K. Lewis, D. M. Hone, Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector. AIDS Res Hum Retroviruses 13, 1187-1194 (1997).

95.       D. W. Pascual, R. J. Powell, G. K. Lewis, D. M. Hone, Oral bacterial vaccine vectors for the delivery of subunit and nucleic acid vaccines to the organized lymphoid tissue of the intestine. Behring Inst Mitt, 143-152 (1997).

96.       J. M. Burns, G. K. Lewis, Improved measurement of calcium mobilization by flow cytometry. Biotechniques 23, 1022-1024, 1026 (1997).

97.       Z. J. Ren et al., Phage display of intact domains at high copy number: a system based on SOC, the small outer capsid protein of bacteriophage T4. Protein science : a publication of the Protein Society 5, 1833-1843 (1996).

98.       R. J. Powell, G. K. Lewis, D. M. Hone, in Vaccines 96: Molecular approaches to the control of infectious disease, F. Brom, E. Nurrhy, D. R. Burton, J. Meckalanos, Eds. (Cold Spring Harbor Press, New York, 1996), pp. 183-187.

99.       S. H. Pincus et al., In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160. AIDS Res Hum Retroviruses 12, 1041-1051 (1996).

100.     D. M. Hone et al., Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. J Biotechnol 44, 203-207 (1996).

101.     M. T. Shata, C. R. Faltynek, G. K. Lewis, R. M. Kamin-Lewis, Absence of high-affinity binding sites for interferon alpha/beta in variant murine CD4+ T lymphocytes not expressing the T cell antigen receptor. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 15, 291-296 (1995).

102.     T. R. Fouts, R. G. Tuskan, S. Chada, D. M. Hone, G. K. Lewis, Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120. Vaccine 13, 1697-1705 (1995).

103.     T. R. Fouts, G. K. Lewis, D. M. Hone, Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine. Vaccine 13, 561-569 (1995).

104.     J. P. Moore, R. L. Willey, G. K. Lewis, J. Robinson, J. Sodroski, Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. Journal of virology 68, 6836-6847 (1994).

105.     R. M. Kamin-Lewis, N. Karasanyi, C. L. Koski, G. K. Lewis, Adherence-mediated T cell activation in multiple sclerosis and other neurological disorders. Journal of neuroimmunology 53, 163-171 (1994).

106.     D. M. Hone et al., Expression of human immunodeficiency virus antigens in an attenuated Salmonella typhi vector vaccine. Developments in biological standardization 82, 159-162 (1994).

107.     Y. H. Abacioglu et al., Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses 10, 371-381 (1994).

108.     S. H. Pincus et al., Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. The Journal of clinical investigation 91, 1987-1996 (1993).

109.     M. V. Parsey, G. K. Lewis, Actin polymerization and pseudopod reorganization accompany anti-CD3-induced growth arrest in Jurkat T cells. J Immunol 151, 1881-1893 (1993).

110.     J. P. Moore et al., Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. Journal of virology 67, 4785-4796 (1993).

111.     J. Moore, G. K. Lewis, J. Robinson, Which gp160 vaccine? Nature 361, 503 (1993).

112.     J. D. Laman et al., A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody. AIDS Res Hum Retroviruses 9, 605-612 (1993).

113.     D. W. Archibald, C. A. Hebert, K. L. Gregory, G. K. Lewis, Effects of human salivas on recombinant HIV-1 proteins. Crit Rev Oral Biol Med 4, 475-478 (1993).

114.     G. K. Lewis, C. P. Feng, Intrinsic immunogenicity of an internal VP1 T-B epitope pair of type 1 poliovirus. Molecular immunology 29, 1477-1485 (1992).

115.     J. D. Laman et al., Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. Journal of virology 66, 1823-1831 (1992).

116.     J. D. Laman et al., Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. Journal of virology 66, 5175 (1992).

117.     G. Bauer et al., Antibodies to HIV-1 in urine of children of HIV-1-infected women. Lancet 340, 559 (1992).

118.     C. R. Faltynek et al., Characterization of the binding of radioiodinated hybrid recombinant IFN-alpha A/D to murine and human lymphoid cell lines. J Interferon Res 10, 55-64 (1990).

119.     C. T. Morita, W. L. Godfrey, J. W. Goodman, G. K. Lewis, Arsonate-specific murine T cell clones. III. Correlation between clonotype expression and fine specificity for analogs of L-tyrosine-p-azobenzenearsonate. J Immunol 137, 2139-2144 (1986).

120.     C. T. Morita, J. W. Goodman, G. K. Lewis, Arsonate-specific murine T cell clones. II. Delayed-type hypersensitivity induced by P-azobenzenearsonate-L-tyrosine (ABA-Tyr). J Immunol 134, 2894-2899 (1985).

121.     P. V. Hornbeck, G. K. Lewis, Idiotype connectance in the immune system. II. A heavy chain variable region idiotope that dominates the antibody response to the p-azobenzenearsonate group is a minor idiotope in the response to trinitrophenyl group. The Journal of experimental medicine 161, 53-71 (1985).

122.     Y. Hayashi et al., Multistep transformation by defined fragments of herpes simplex virus type 2 DNA: oncogenic region and its gene product. Proc Natl Acad Sci U S A 82, 8493-8497 (1985).

123.     G. I. Evan, G. K. Lewis, G. Ramsay, J. M. Bishop, Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Molecular and cellular biology 5, 3610-3616 (1985).

124.     J. D. Conger, G. K. Lewis, J. W. Goodman, Idiotypic properties of the murine anti-arsonate antibody response: B- and T-cell influences. Cellular immunology 95, 173-179 (1985).

125.     R. A. Barry et al., Antibodies to the scrapie protein decorate prion rods. J Immunol 135, 603-613 (1985).

126.     Z. Kaymakcalan, D. E. Nitecki, G. K. Lewis, J. W. Goodman, Differential induction of help and suppression in mice by bifunctional antigens administered via different routes. Molecular immunology 21, 529-536 (1984).

127.     W. L. Godfrey, G. K. Lewis, J. W. Goodman, The anatomy of an antigen molecule: functional subregions of L-tyrosine-p-azobenzenearsonate. Molecular immunology 21, 969-978 (1984).

128.     G. I. Evan, G. K. Lewis, J. M. Bishop, Isolation of monoclonal antibodies specific for products of avian oncogene myb. Molecular and cellular biology 4, 2843-2850 (1984).

129.     G. K. Lewis, Z. Kaymakcalan, J. Yao, J. W. Goodman, Idiotype connection between anti-arsonate and anti-dinitrophenyl responses in BALB/c mice. Annals of the New York Academy of Sciences 418, 282-289 (1983).

130.     P. V. Hornbeck, G. K. Lewis, Idiotype connectance in the immune system. I. Expression of a cross-reactive idiotype on induced anti-p-azophenylarsonate antibodies and on endogenous antibodies not specific for arsonate. The Journal of experimental medicine 157, 1116-1136 (1983).

131.     B. Hertel-Wulff, J. W. Goodman, C. G. Fathman, G. K. Lewis, Arsonate-specific murine T cell clones. I. Genetic control and antigen specificity. The Journal of experimental medicine 157, 987-997 (1983).

132.     J. D. Conger, E. Lamoyi, G. K. Lewis, A. Nisonoff, J. W. Goodman, Idiotype profile of an immune response. II. Reversal of the relative dominance of major and minor cross-reactive idiotypes in arsonate-specific T-independent responses. The Journal of experimental medicine 158, 438-451 (1983).

133.     G. K. Lewis, P. V. Hornbeck, Strange connections in the unspecific parallel set. Surv Immunol Res 1, 262-267 (1982).

134.     D. Prim, G. K. Lewis, J. W. Goodman, Anti-idiotypic specificity of T cell help induced by concanavalin A. International archives of allergy and applied immunology 66 Suppl 1, 212-217 (1981).

135.     J. D. Conger, G. K. Lewis, J. W. Goodman, Idiotype profile of an immune response. I. Contrasts in idiotypic dominance between primary and secondary responses and between IgM and IgG plaque-forming cells. The Journal of experimental medicine 153, 1173-1186 (1981).

136.     N. H. Ruddle, B. Beezley, G. K. Lewis, J. W. Goodman, Antigen specific T cell hybrids--II. T cell hybrids which bind azobenzenearsonate. Molecular immunology 17, 925-931 (1980).

137.     D. Primi, G. K. Lewis, J. W. Goodman, The role of immunoglobulin receptors and T cell mediators in B lymphocyte activation. I. B cell activation by anti-immunoglobulin and anti-idiotype reagents. J Immunol 125, 1286-1292 (1980).

138.     J. W. Goodman, G. K. Lewis, D. Primi, P. Hornbeck, N. H. Ruddle, Antigen-specific molecules from murine T lymphocytes and T cell hybridomas. Molecular immunology 17, 933-945 (1980).

139.     P. Chen, D. E. Nitecki, G. K. Lewis, J. W. Goodman, Antigen structural requirements for immunoglobulin isotype switching in mice. The Journal of experimental medicine 152, 1670-1683 (1980).

140.     D. Primi, G. K. Lewis, R. Triglia, J. W. Goodman, Rosette formation between murine lymphocytes and erythrocytes. A new locus in the H-2 region. The Journal of experimental medicine 149, 1349-1359 (1979).

141.     D. Primi, G. K. Lewis, J. W. Goodman, Composite activities on B cells of products released by T cells activated by concanavalin A. European journal of immunology 9, 607-612 (1979).

142.     D. Primi, G. K. Lewis, J. W. Goodman, A hemolytic plaque assay for activated murine T cells. The Journal of experimental medicine 150, 987-1000 (1979).

143.     G. K. Lewis, J. W. Goodman, R. Ranken, Activation of B cell subsets by T-dependent and T-independent antigens. Advances in experimental medicine and biology 98, 339-356 (1978).

144.     G. K. Lewis, J. W. Goodman, Purification of functional, determinant-specific, idiotype-bearing murine T cells. The Journal of experimental medicine 148, 915-924 (1978).

145.     J. W. Goodman et al., Antigen structure and lymphocyte activation. Immunological reviews 39, 36-59 (1978).

146.     J. W. Goodman et al., T-lymphocyte activation by immunogenic determinants. Advances in experimental medicine and biology 98, 143-164 (1978).

147.     G. K. Lewis, R. Ranken, J. W. Goodman, Complement-dependent and -independent pathways of T cell-B cell cooperation. J Immunol 118, 1744-1747 (1977).

148.     G. K. Lewis, J. W. Goodman, Carrier-directed anti-hapten responses by B-cell subsets. The Journal of experimental medicine 146, 1-10 (1977).

149.     G. K. Lewis, R. Ranken, D. E. Nitecki, J. W. Goodman, Murine B-cell subpopulations responsive to T-dependent and T-independent antigens. The Journal of experimental medicine 144, 382-397 (1976).

150.     H. D. Whitten, J. M. Cruse, G. K. Lewis, E. S. Watson, Antigen driven selection for Fc receptors of enhancing antibody on macrophages during an alloimmune response. J Reticuloendothel Soc 15, 118-125 (1974).

151.     J. M. Cruse et al., Mechanisms of immunological enhancement. Prog Exp Tumor Res 19, 110-156 (1974).

152.     J. M. Cruse et al., Fate of murine fibrosarcoma allografts and radiolabeled tumor-enhancing IgG2, normal (nonenhancing) IgG2 and bacterial endotoxin in endotoxin-tolerant and nontolerant mice. J Reticuloendothel Soc 15, 75-84 (1974).

153.     J. M. Cruse, H. D. Whitten, G. K. Lewis, E. S. Watson, Facilitation of macrophage-mediated destruction of allogeneic fibrosarcoma cells by tumor-enhancing IgG 2 in vitro. Transplant Proc 5, 961-967 (1973).

154.     J. M. Cruse et al., Prolonged survival of murine fibrosarcoma allotransplants by anti-enhancing Fab alloantibody. Immunol Commun 1, 367-373 (1972).

155.     J. M. Cruse et al., A synergistic immunosuppressive effect of endotoxin and PHA-M on immunologic enhancement in mice. Z Immunitatsforsch Exp Klin Immunol 143, 31-42 (1972).

156.     J. M. Cruse et al., Dissection of the immunosuppressive effect of the Fc region of tumor-enhancing IgG. Z Immunitatsforsch Exp Klin Immunol 143, 43-58 (1972).

 

Research Interests

HIV Vaccine Development, Structural and Functional Basis of Fc-mediated Effector Function

Awards and Affiliations

  • 1970 - Phi Kappa Phi (National Scholastic Honorary Society)
  • 1970-1971: University Non-Service Graduate Fellowship
  • 1971-1974: Department of Biology Research Fellowship
  • 1974-1976: NIH Postdoctoral Fellowship (Training Grant)
  • 1976-1977: NIH Postdoctoral Fellowship (Individual Grant)
  • 1983-1988: American Cancer Society Faculty Research Award
  • 2016: The Robert C. Gallo, M.D., Professor in Translational Medicine (Endowed Professorship)

 

Professional Activity

Administrative Service

  • 1980-1984: UCSF, Academic Senate Research Grant Committee
  • 1985-1996: UMBI, Medical Biotechnology Center, Scientific Advisor
  • 1985-1986: UMB, Dean’s Committee on Molecular Biology at UMB
  • 1986-1987: UMB, Biochemistry Faculty Search Committee
  • 1989-1991: UMB, Chair, Virology Search Committee, Department of Microbiology and Immunology
  • 1995-1996: UMB, Member, Dean’s Committee on Revision of Appointment and Promotions Requirement
  • 1997-2007: Chairperson, UMBI, IACUC
  • 2007-2013: Member, UMB, IACUC

National Service

  • 1981-1988: Immunologic Research (Associate Editor
  • 1991-1993: Clinical Biotechnology (Associate Editor)
  • 1996-1999: Cellular Immunology (Associate Editor)
  • 1996-2001: Journal of Human Virology (Section Editor)
  • 2006-2102: Editor, Infections and Cancer
  • 2006 - Present: Associate Editor Bioengineered Bugs

Ad Hoc Reviewer

  • Science Magazine
  • PNAS
  • Biochemistry
  • Journal of Immunology
  • Molecular Immunology
  • Infection and Immunity
  • Journal of Virology
  • Vaccine
  • Gene Therapy
  • AIDS
  • J. AIDS
  • AIDS Research and Human Retroviruses
  • Clinical and Vaccine Immunology
  • PlosPathogens
  • Journal of Clinical Investigation

National Review Panels

  • Ad Hoc Reviewer for NIAID AIDS Review Study Sections 1987-1995
  • Ad Hoc Reviewer for NSF
    • Ad Hoc Reviewer for the National Foundation
    • NIDA Review Panel, 1991-1994
  • NIDA Advisory Panel for Immunomodulatory Effects of Abused Drugs, 1991 -1994.
  • Extramural Review of Biological Response Modifiers Program, Office of the Director, 1991.
  • NIH Office of AIDS Research, FY 1996 Planning Workshop, March 1994.
  • NIH Ad Hoc Study Section to Review IPCAVD Applications, November 1998 (Chairperson)
  • NIH Ad Hoc Study Section to Review HIVRAD Applications, March 1999.
  • NIH Ad Hoc Study Section to Review AIDS Drug Development Applications, March 2003 (Chairperson)
  • NIH Ad Hoc Study Section to Review IPCAVD Applications, March 2004 (Chairperson)
  • NIH AIDSRC Study Section full member 1996-2003, Charperson 2001-2003
  • NIH MIDRC Study Section, Full Member 2003-2007, Chairperson 2004-2007
  • Regular Panel Member, Department of Defense, Military Infectious Disease Research Program, 2004- currently
  • NIH AIDS Immunology and Pathogenesis Study Section, Member, 2012- 2016
  • NIAID AIDS Vaccine Research Subcommittee, 2016-

Industrial Consulting

  • 1981-1984: Consultant, 3M Diagnostics, Mountain View, CA
  • 1982-1988: Founding Member, Intek Diagnostics, Burlingame, CA
  • 1992-1996: Consultant, Rand Medical Corporation, Baltimore, MD
  • 1994-1995: Consultant, Immunoogics Corp., Waltham, MA
  • 1996-1999: Board Member, Biotechnology Transfer, Columbia, MD
  • 2003-2009: Scientific Advisory Board and Founder, Profectus Biosciences, Baltimore, MD
  • 2007-2007: Consultant, Novartis Venture Capital, Basel, Switzerland